
Episode 21: Alan Ho live (post hoc) from the Multidisciplinary Head and Neck Cancers Symposium
5/31/2026
0:00
39:56
Alan Ho, Medical oncologist at MSKCC talks us through his work around Ozuriftamab Vedotin (Oz-V) and other ADC approaches. Ben criticises Will's combination approaches.
More episodes from "Deep Margin"



Don't miss an episode of “Deep Margin” and subscribe to it in the GetPodcast app.








